Skip to content

Author

A. Anazodo

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study.

PURPOSE Selpercatinib, a highly selective oral RET inhibitor with CNS activity, has previously demonstrated durable responses and an acceptable safety profile in adults with RET-driven cancers. Consequently, the safety and efficacy of selpercatinib were investigated in pediatric/adolescent participants. METHODS LIBRE...

T. Laetsch, H. Kang, M. Casanova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.